Jounce Therapeutics Says JTX-8064/Pimivalimab Shows Deep, Durable Responses In Pretreated Ovarian Cancer Patients

Author: Vandana Singh | March 17, 2023 11:30am

 

 

• Jounce Therapeutics Inc (NASDAQ:JNCE) announced results from the pre-planned data review of the INNATE Phase 2 Trial of JTX-8064 and pimivalimab in patients with advanced solid tumors. 


• Data exhibited that patients in the ovarian cancer combination cohort with platinum-resistant ovarian cancer are experiencing deep and durable responses based on a pre-planned informal data review.


• In this cohort, 35 patients with third- and fourth-line platinum-resistant ovarian cancer were treated with JTX-8064 and Jounce's PD-1 inhibitor, pimivalimab. 


• There were five responders, four of whom are confirmed, with all five patients remaining on study for over six months with continued tumor reduction over time. 


• In patients with one to six prior lines of therapy for ovarian cancer, pembrolizumab monotherapy demonstrated a response rate of 8.5%, with a duration of response of 10.2 months. 


• Two of the five responders in INNATE have a PD-L1 score of zero, indicating a low likelihood of response to a PD-1 inhibitor. 


• The combination was well tolerated with <10% of patients reporting Grade 3 or greater related adverse events.


• In addition to the patients with ovarian cancer, both durable responses and stable disease have occurred in patients with renal cell carcinoma, biliary tract cancer, and first-line and second/third-line head and neck squamous cell carcinoma.


• As previously announced, Jounce is seeking to partner JTX-8064.


• Recently, the company confirmed receiving Concentra Biosciences LLC's unsolicited and non-binding proposal to acquire 100% of the equity of Jounce.


• JNCE Price Action: Jounce Therapeutics shares are up 2.24% at $1.60 on the last check Friday.


 

 

 

 

Posted In: JNCE